Skip to main content
OpenTrials
Completed

NCT Number: NCT05002647

Relationship Between the Clinical Pharmacist & Antibiotic Use by Using the Electronic Program

A retrospective cohort study to explore the association between clinical pharmacists' interventions and antibiotic consumption through the use of the medical electronic reports and to identify mortality and cost savings in hospital infectious disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Clinical Pharmacists Electronic Medical Record

Sex eligibility

All sexes

Study type

Observational

Primary location

Ministers of health

Alexandria, 22511, Egypt

About this study

The role of clinical pharmacist includes :

  • a check of suitable selection and dosing of antimicrobials according to the diagnosis, type of infection, antimicrobial cultures as possible, comorbidities of patients (renal or hepatic function, etc), adverse effect, and drug interaction with other drugs.
  • Documentation of the clinical intervention, cost-saving, adverse effect,, antimicrobial culture and antimicrobial consumption on the electronic program (CPC "clinical patient care").
  • The clinical pharmacist inspector reviews the data recorded on CPC.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All inpatient with infectious disease (disorders caused by organisms as (bacteria, viruses, fungi, or parasites).

Exclusion criteria

  • Any other cause of hospital admission other than infectious disease.

Treatment and study plan

No intervention

Other

There is no intervention

Primary outcomes

  1. Antimicrobial consumption

    Time frame: 2 years

    consumption of antimicrobials (defined daily doses / 100 patient-days)

  2. Days of therapy (DOT)

    Time frame: 2 years

    Number of days of each antimicrobial received for therapy

  3. Length of therapy(LOT)

    Time frame: 2 years

    The number of days a patient takes an antibacterial drug, regardless of the number of different medications

Secondary outcomes

  1. cost savings

    Time frame: 2 years

    (initial treatment cost × days before intervention) - (cost after intervention × days with this treatment),

  2. Mortality rate

    Time frame: 2 years

    in-hospital mortality rate (%)

  3. Antimicrobial resistance

    Time frame: 2 years

    resistance defined as resistance to at least one antimicrobial from the panel for all organisms, and for a subset of organisms belonging to the ESKAPE group (Enterococcus faecium, S. aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp.

  4. The incidence of adverse reaction of antimicrobial

    Time frame: 2 years

    An unexpected medical problem that happens during treatment with antimicrobial.

Sponsors and collaborators

Lead sponsor

Alexandria University

Other

Collaborators

  • Ministry of Health and Population, Egypt

Registry information

Official study title

Relationship Between the Clinical Pharmacist & Antibiotic Use in Selected Infectious Disease Hospitals in El Beheira by Using the Electronic Program, Retrospective Cohort

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 12, 2021
Registry last updated
Dec 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.